Arvinas, Inc, announced that its chief commercial officer, John Northcott, is stepping down as of mid-January. 1 While the ...

Ash Shehata from KPMG discusses how artificial technology has a lot to prove, although investors still see a lot of potential in it.

The trial, developed in collaboration with Novotech, will specifically target dietary and alcohol-induced overindulgence.

The cobas liat test aims to improve patient outcomes by offering rapid, accurate results in decentralized and community-based ...

Expanded GTM services aim to ensure members receive tests at the optimal times while cutting down on testing misuse.

PharmaScroll announced a new generative AI chatbot called Self-Serve AI. 1 The company describes it as a research and ...

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses AD04’s development timeline and next steps towards approval for alcohol use disorder.

Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

As investors react to an ever-changing political climate, Ash Shehata from KPMG explains what factors they're paying ...

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...